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Abstract
Background: The availability of cell lines releasing fluorescent viral particles can significantly
support a variety of investigations, including the study of virus-cell interaction and the screening of
antiviral compounds. Regarding HIV-1, the recovery of such biologic reagents represents a very
hard challenge due to the intrinsic cytotoxicity of many HIV-1 products. We sought to overcome
such a limitation by using a cell line releasing HIV-1 particles in an inducible way, and by exploiting
the ability of a HIV-1 Nef mutant to be incorporated in virions at quite high levels.
Results: Here, we report the isolation and characterization of a HIV-1 packaging cell line, termed
18-4s, able to release valuable amounts of fluorescent HIV-1 based Virus-Like Particles (VLPs) in an
inducible way. 18-4s cells were recovered by constitutively expressing the HIV-1 NefG3C mutant
fused with the enhanced-green fluorescent protein (NefG3C-GFP) in a previously isolated inducible
HIV-1 packaging cell line. The G3C mutation creates a palmitoylation site which results in NefG3C-
GFP incorporation into virions greatly exceeding that of the wild type counterpart. Upon induction
of 18-4s cells with ponasterone A and sodium butyrate, up to 4 µg/ml of VLPs, which had
incorporated about 150 molecules of NefG3C-GFP per viral particle, were released into the
culture supernatant. Due to their intrinsic strong fluorescence, the 18-4s VLPs were easily
detectable by a novel cytofluorometric-based assay developed here. The treatment of target cells
with fluorescent 18-4 VLPs pseudotyped with different glycoprotein receptors resulted in these
becoming fluorescent as early as two hours post-challenge.
Conclusion: We created a stable cell line releasing fluorescent HIV-1 based VLPs upon induction
useful for several applications including the study of virus-cell interactions and the screening of
antiviral compounds.
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Background
Fluorescent viral particles represent an extremely useful
tool for the study of virus-cell interaction. For this reason
many efforts have been devoted to the recovery of fluores-
cent viruses of different species, including herpesviruses
[1,2], adenoviruses [3], rhabdoviruses [4], and the African
swine fever virus [5]. Concerning HIV, on the one hand,
virions which lead to only the infected cell becoming flu-
orescent were generated by replacing the nef gene with the
enhanced green fluorescent protein (gfp) gene [6] or by
inserting a gfp-ires cassette upstream to nef [7]. On the
other hand, HIV particles, which themselves were fluores-
cent due to the incorporation of a fluorescent fusion pro-
tein, were generated by inserting the gfp gene between the
matrix and capsid Gag sequences [8]. Of note, however,
such engineered HIV-1 derivatives, although replication-
competent, suffer of limitations in their replication effi-
ciency. As an alternative to insertion of the GFP gene into
the viral genome, fluorescent HIV-1 virions were gener-
ated by co-expressing a wild-type HIV-1 genome with the
GFP-Vpr fusion product [9,10]. In this case, the fluores-
cent signal is detectable only in the first replication cycle,
and persist until it is intracellularly degraded. Up until
now, fluorescent viral particles have been generated by
transient transfection procedures and cell lines stably
releasing such particles have not yet been available.
Similarly to Vpr, the HIV Nef protein is incorporated in
HIV-1 particles, even if at lower levels, i.e. approximately
10 molecules per virion [11-13]. The Nef virion incorpo-
ration depends on its localization at the cell membrane.
This, in turn, depends on its N-terminus myristoylation
marked by the presence of a glycine residue at the position
2, as well as on the presence of two clusters of basic amino
acids at the N-terminal region, i.e. two lysines at the posi-
tions 4 and 7 and four arginines within the region of
amino acid 17–22 [14].
HIV is thought to bud at level of the so called "detergent-
resistant microdomains" (rafts) [15], that are regions
within the cell membranes enriched in cholesterol and
sphingolipids. Several authors demonstrated the presence
of Nef in rafts [16-19], even if the relative biologic signif-
icance has to be clarified yet. In any case, Nef has been
found associating poorly (from 2 to 5%) to lipid rafts
[20], and this may account for the low amounts of Nef
incorporated into the virions. Hence, a more efficient Nef
localization at the lipid raft is expected to increase its viral
incorporation. This was indeed the case of the HIV-1 Nef
double mutant V153L, E177G we recently described, whose
strong raft localization leads to a virion incorporation
about 100-fold more efficient than its wt counterpart [21].
Palmitoylation is a reversible post-translational protein
fatty acylation generally occurring on cysteine residues
located close to domains interacting with cell membranes.
Such a modification regulates the intracellular protein
trafficking and the disposition at the cell membrane rafts.
In this regard, it was recently demonstrated that the Nef
palmitoylation produced by mutating the Gly 3 to Cys
increases the raft localization up to 12-fold compared
with wt Nef [20,22]. By consequence, it could be antici-
pated that palmitoylated Nef undergoes virion incorpora-
tion with an efficiency significantly higher than the wild-
type counterpart.
Here, we report that a fusion protein consisting of palmi-
toylated Nef mutant and the green-fluorescent protein
(NefG3C-GFP) was efficiently incorporated into HIV-1
particles. In order to generate a stable source of fluores-
cent HIV-1 virus-like particles (VLPs), we have then stably
introduced an expression vector for NefG3C-GFP into a
previously described inducibly regulated 293-based HIV-
1 packaging cell line. Upon induction of these cells (18-
4s), high amounts of fluorescent HIV-1-based VLPs were
produced which may be employed for both basic research
and antiviral screening.
Results
NefG3C-GFP is incorporated in HIV-1 virions at high levels
The N-terminal palmitoylation significantly increases the
localization at the cell membrane rafts of Nef both in its
native form [20] and when fused with GFP [22]. Thus,
since rafts are the sites from where HIV preferentially buds
[15], we expected that the NefG3C-GFP fusion product
would be incorporated into virions at levels which would
be high enough to result in the HIV-1 particles being
highly fluorescent. To validate such a prediction, we com-
pared the levels of incorporation of NefG3C-GFP into vir-
ions with those of wt Nef and wt Nef-GFP. In addition, the
virion associated amounts of NefG3C-GFP were com-
pared with those of GFP-Vpr, already known to incorpo-
rate efficiently in viral particles [9,10]. We co-transfected
293T cells with the pCMV∆R8.74 HIV-1 packaging con-
struct together with vectors expressing each of the above
HIV-1 protein derivatives. Forty-eight hours later, the
supernatants were harvested, clarified, and the VLPs puri-
fied and analyzed by Western blot for the incorporation of
Nef- or GFP-derivatives. We observed that equal amounts
of viral particles gave rise to NefG3C-GFP signals much
stronger than those produced by both wt Nef and wt Nef-
GFP (Figure 1A), and also slightly more intense compared
with GFP-Vpr (Figure 1B). This suggests that NefG3C-GFP
is incorporated at high levels in HIV-1 viral particles.
Since NefG3C strongly associates with cell membranes
[20,22], it is conceivable that at least part of the NefG3C-
GFP we detected was associated with microvesicles and/or
exosomes rather than to viral particles. To test this possi-
bility, we transfected 293T cells with the NefG3C-GFPBMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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NefG3C-GFP incorporates at high levels in HIV-1 based VLPs Figure 1
NefG3C-GFP incorporates at high levels in HIV-1 based VLPs. Western blot analysis for the virion incorporation of 
NefG3C-GFP as compared with wt Nef and wt Nef-GFP (A) or with GFP-Vpr (B). 293T cells were transfected with the 
pCMV∆R8.74 HIV-1 packaging vector together with vectors expressing either wt Nef, wt Nef-GFP, or GFP-Vpr in 1:1 molar 
ratio. Forty-eight hours later, supernatants were harvested, and the VLPs purified on a 20% sucrose cushion. Then, the VLP 
concentrations were measured by a quantitative anti-HIV-1 CAp24 ELISA, and 100 ng of VLPs were analyzed by Western blot 
using a 1:1000 dilution of the ARP444 anti-Nef polyclonal Abs, a 1:200 dilution of the 6.2 anti-Nef mAb (A), or a 1:500 dilution 
of an anti-GFP mAb (B). As negative control (Ctrl-), 100 ng of empty VLPs were used in both cases. In addition, 50 µg of the 
lysates from the producer cells were probed for the expression of HIV-1 CAp24, Nef-, and GFP-related products. (C) Anti-
Nef Western blot analysis of the indicated volumes of 100-fold concentrated and purified supernatants from 5 × 106 293T cells 
transfected with the NefG3C-GFP expression vector alone or together with the pCMV∆R8.74 HIV-1 packaging vector in a 1:1 
molar ratio. In the here presented experiment, the virion concentration in the preparation from the cells transfected with the 
HIV-1 packaging vector was 3 ng/µl of CAp24. Also, 50 µg of the lysates from transfected cells were analyzed for the NefG3C-
GFP expression. Data are representative of 9 (A), 3 (B), and 2 (C) independent experiments. The migration of major viral 
products are indicated on the left side, whereas the molecular marker sizes are reported on the right.
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expressing vector alone or together with the pCMV∆R8.74
HIV-1 packaging construct. Forty-eight hours later, the
supernatants were harvested, concentrated and purified as
above described, and equal volumes of each preparation
were analyzed by anti-Nef Western blot. As shown in Fig-
ure 1C, no detectable amounts of NefG3C-GFP were
found in supernatants from 293T cells transfected in the
absence of the HIV-1 packaging construct. This strongly
suggests that the most part of NefG3C-GFP molecules we
detected in supernatants from the cells co-transfected with
the HIV-1 packaging construct were indeed associated
with viral particles.
These data strongly support the hypothesis that Nef
palmitoylation results in a significant increase in virion
incorporation levels which was the basis to attempt the
generation of cells stably releasing VLPs with incorporated
NefG3C-GFP.
Isolation and induction of the 18-4s cell line stably 
expressing the NefG3C-GFP fusion product
We have used the 293 Rev-Gag-Pol [23] (henceforth
referred to as 293/RGP) as a platform for the generation of
stable cells releasing fluorescent HIV-1 based VLPs. 293/
RGP cells are packaging cells for HIV-1 derived vectors
inducibly expressing and releasing HIV-1 VLPs. In the
293/RGP cells, the HIV-gag-pol gene and the HIV-rev are
separately expressed under the control an ecdysone-
inducible promoter (for a review, see [24]) so that particle
production requires addition of the ecdysone analogue
ponasterone A (PonA) to the medium.
293/RGP cells were co-transfected with the vectors
expressing the NefG3C-GFP fusion product and the p75
human Nerve Growth factor receptor truncated in its
intracytoplasmic domain (∆NGFr). Indeed, the expres-
sion of this marker was useful in the first selection steps,
when the cell sorter-based selection led the cells to an
unacceptable cell mortality. In this respect, after two anti-
NGFr selections followed by two GFP-based cell sorting,
we recovered a cell population (18-4s cells) more than
95% positive for the NefG3C-GFP expression (Figure 2A).
Of note, at the FACs analysis 18-4s cells actually appeared
as two distinct sub-populations in terms of the expression
of both NefG3C-GFP and ∆NGFr. 18-4s cell grew with a
similar duplication time to that of the parental cells (not
shown), but tended to float much more easily. The levels
of NefG3C-GFP remained stable during two months
period in culture, but progressively declining thereafter
(not shown). This appeared to be the consequence of the
silencing rather than the loss of the NefG3C-GFP
sequences, since treatment with sodium butyrate restored
a GFP FACs profile similar to early-passage cells (not
shown).
We then sought to establish the best experimental condi-
tions for the induction of the expression of HIV-1 prod-
ucts in 18-4s cells. Following the methods previously
described for the 293/RGP cells [23], we treated 18-4s
cells with 5 mM sodium butyrate and/or PonA 2 µM, and
monitored the expression of HIV-1 CAp24 and NefG3C-
GFP by FACs two and three days later. Specifically, 293/
RGP and 18-4s cells were treated with: i) PonA alone; ii)
both PonA and sodium butyrate for one day and, thereaf-
ter, with PonA alone, or iii) with PonA and sodium
butyrate. As shown in Figure 2B, the treatment with PonA
alone resulted in inefficient expression of Gag products in
18-4s cells, while more than 50% of the parental 293/RGP
cells was induced to express Gag products. The addition of
sodium butyrate was mandatory for significant Gag
induction in 18-4s cells. In fact, a pulse of sodium
butyrate for 24 h resulted in 60% of the cells expressing
Gag whereas its continuous presence for the 48 h induc-
tion period further increased the percentage of positive
cells to 77%. Additionally, the expression of NefG3C-GFP
was increased 3–4 fold. Sodium butyrate treatment
increased also the percentage of Gag positive 293/RGP
cells from 57% to more than 80%, and improved the rel-
ative mean fluorescence intensity by 2–2.5 fold. Of note,
in 18-4s cells the treatment with sodium butyrate alone
led to an increase of the NefG3C-GFP expression similar
to that induced also in the presence of PonA (not shown).
No remarkable differences in terms of expression of both
CAp24 and NefG3C-GFP were observed between the cells
harvested at the day 2 and at the day 3 (not shown). At
this time, however, the cell cultures suffered of some cell
mortality (not shown).
Finally, the intracellular localization of NefG3C-GFP we
analyzed by fluorescence microscope seemed qualitatively
similar to that already described for wt Nef [25] in the
presence, however, of a stronger localization at the cell
membrane (not shown).
Dose-response of the PonA induced production of VLPs 
from 18-4s cells
Clearly, the most relevant feature of 18-4s cells was
expected to be the ability to produce fluorescent VLPs. In
this regard, the VLP production efficiency was assayed by
inducing 18-4s cells with increasing concentrations of
PonA in the presence of the optimal doses of sodium
butyrate (i.e., 5 mM) that was mandatory for the expres-
sion of HIV-1 CAp24 and related products. As for 293/
RGP, 18-4s cells produced VLPs at concentrations that
increased with the doses of PonA up to 2 µM (Figure 3).
Higher doses of PonA did not further increase the
amounts of produced VLPs (not shown). At the highest
concentrations of PonA, 18-4s cells produced amounts of
VLPs equivalent to up to 4 µg/ml. However, these levels
were still 2–3 fold lower compared with those from theBMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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Analysis of the expression of the transfected vectors in control or induced 18-4s cells Figure 2
Analysis of the expression of the transfected vectors in control or induced 18-4s cells. (A). Analysis of the expres-
sion of NefG3C-GFP and ∆NGFr in non induced 18-4s cells. Seven days after the last cell sorter purification step, the cells 
were labeled with unspecific IgG (I) or with anti-human NGFr mAb (II) and analyzed by FACs. Quadrants were set on the basis 
of the fluorescence levels of 293/RGP cells labeled with anti-NGFr mAb. (B) FACs analysis for the expression of both NefG3C-
GFP and HIV-1 CAp24-related products in 18-4s cells treated with: i) 2 µM PonA; ii) 2 µM PonA and 5 mM sodium butyrate 
for one day and, thereafter, with 2 µM PonA alone, or iii) 2 µM PonA and 5 mM sodium butyrate. The cells harvested two days 
after the induction were permeabilized and labeled with a 1:100 dilution of the anti-CAp24 KC-57 PE-conjugated mAb. 293/
RGP cells were used as control. Both the percentages and the mean fluorescence values referred to CAp24- and, in the case of 
18-4s cells, also to the GFP-related fluorescence are reported in the respective quadrants. NaB: sodium butyrate. The results 
are representative of 3 independent experiments.
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parental cells. This could be the consequence of the incor-
poration of the high number of NefG3C-GFP molecules
that may in some way decrease the efficiency of the HIV
assembling/budding process.
Characterization of NefG3C-GFP VLPs
Next, we molecularly characterized the VLPs released by
18-4s cells. The Western blot analysis for the cell associ-
ated HIV-1 Gag-related products did not show significant
differences compared with the parental cells, while the
anti-Nef Western blot analysis, consistently with the here
above reported results, revealed an induction-dependent
apparent increase of the NefG3C-GFP expression (Figure
4A). Concerning the VLP molecular composition, no sig-
nificant differences were detected in the contents of Gag-
related products between HIV-1 and VLPs from 293/RGP
or 18-4s cells. On the other hand, and of a major rele-
vance, remarkable amounts of NefG3C-GFP molecules
appeared to be associated with the VLPs from 18-4s cells,
as also confirmed by the anti-GFP Western blot analysis
(not shown). However, in order to ensure that the
NefG3C-GFP molecules we detected were indeed incorpo-
rated and not just associated with their surface, we addi-
tionally performed Western blot analysis after a
proteolytic treatment of the VLPs. Thus, VLPs from 18-4s
which had been pseudotyped with the glycoprotein recep-
tor of the Vesicular Stomatitis virus (VSV-G) were treated
with the subtilisin A protease and analyzed for the pres-
ence of both NefG3C-GFP and VSV-G. Such a treatment
was expected to degrade the viral surface proteins as well
as any products non specifically associated with the viral
envelope, but should not affect genuinely incorporated
proteins. As shown in Figure 4B, while the NefG3C-GFP
related signal appeared substantially unaffected by the
subtilisin A treatment, the VSV-G receptor resulted effi-
ciently degraded. To further support the idea that the Nef-
related signals we detected by Western blot analysis
indeed originated from virion incorporated NefG3C-GFP
molecules, VLPs were purified through a iodixanol gradi-
ent, and the recovered fractions analyzed by Western blot
(Figure 4C). The co-sedimentation of NefG3C-GFP and
CAp24 strengthens the conclusion that NefG3C-GFP mol-
ecules are indeed incorporated in VLPs.
Furthermore, we were interested in estimating the number
of molecules incorporated in the VLPs released from
induced 18-4s cells. To this end, we compared the inten-
sity of the signals from decreasing amounts of recom-
binant (r) Nef with those from decreasing amounts of
VLPs whose contents in CAp24 were preventively and rig-
orously established by quantitative ELISA (Figure 4D). On
the basis of the densitometric analysis carried out on the
Western blot films (not shown), we estimated that 20 ng
of 18-4s VLPs contain approximately 1.25 ng of NefG3C-
GFP molecules. Considering the purity of rNef prepara-
tion (i.e., 95%), the differences in the molecular weight
between CAp24 and NefG3C-GFP, and that it was
reported that HIV-1 particles incorporate approximately
5,000 molecules of CAp24 per virion [26], we calculated
the presence of about 150 NefG3C-GFP molecules per
VLP. Such an estimation cannot take account of possible
differences in the antibody recognition between NefG3C-
GFP and wt rNef. These, however, are not expected to be
of a major relevance since the anti-Nef polyclonal Abs
preparation we employed was recovered using a full-
length wt rNef derivative as immunogen.
Finally, we analyzed the morphology of the VLPs released
by induced 18-4s cells by electron microscope as com-
pared with VLPs from parental 293/RGP cells. Clearly, 18-
4s cells released VLPs with a morphology very similar to
that of the VLPs from parental cells (Figure 5A–B), thus
suggesting that the NefG3C-GFP incorporation did not
The efficiency of VLP production from 18-4s cells depends  on the PonA concentration Figure 3
The efficiency of VLP production from 18-4s cells 
depends on the PonA concentration. PonA dose-
response of the VLP production from 18-4s cells as com-
pared with the parental 293/RGP cells. The cells were culti-
vated for 3 days in the presence of 5 mM sodium butyrate 
together with increasing doses of PonA. Supernatants were 
clarified and the VLP contents measured as concentrations of 
HIV-1 CAp24. The mean values ± s.e. from the data of three 
independent experiments are reported.
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Molecular analysis of the HIV-1 related products in 18-4s cells and VLPs Figure 4
Molecular analysis of the HIV-1 related products in 18-4s cells and VLPs. (A). Western blot analysis for the cell 
expression and VLP incorporation of both HIV-1 Gag-related products and NefG3C-GFP in control and/or induced 18-4s and 
parental 293/RGP cells. As control, both cell and viral lysates from HIV-1 pNL4-3 transfected 293T cells were used. Fifty µg of 
total proteins from each cell lysate or 50 ng of VLPs were assayed using a 1:1000 dilution of pooled strongly HIV-1 positive 
human sera, or a 1:1000 dilution of the ARP444 anti-Nef sheep antiserum. NaB: sodium butyrate. (B) Western blot analysis of 
subtilisin A treated 18-4s VLPs. Hundred ng of (VSV-G) NefG3C-GFP VLPs were treated with 10 µg of subtilisin A or with an 
equal amount of bovine serum albumine (Ctrl) and, after 2 hours of incubation at 37°C, the reaction was stopped with phenyl-
methylsulfonyl fluoride, and the samples analyzed for both NefG3C-GFP and VSV-G contents by Western blot using the 
ARP444 anti-Nef polyclonal Abs or anti-VSV-G polyclonal Abs recognizing the VSV-G intracytoplasmic tail. The lowest signals 
overlaps the front-dye of the SDS-PAGE where degraded protein products are expected to accumulate. (C) Anti-Nef and anti-
CAp24 Western blot analysis of relevant fractions from an iodixanol gradient loaded with 18-4s VLPs. Fifteen ml of supernatant 
from induced 18-4s cells containing about 50 µg of VLPs were concentrated by ultracentrifugation on a 20% sucrose cushion, 
and loaded on a 6 to 35% discontinuous iodixanol gradient. The Western blot analysis of the eight most relevant fractions out 
of the fifteen harvested is reported. (D) Quantitation of NefG3C-GFP virion incorporation. Two-fold serial dilutions of 18-4s 
VLPs were analyzed by Western blot for the presence of NefG3C-GFP as compared with serial dilutions of rNef. The nano-
grams of rNef and 18-4s VLPs, the latter measured by quantitative anti-CAp24 ELISA, are indicated on the top. Data are repre-
sentative of 8 (A), 3 (B), and 2 (D) independent experiments. For all panels, the migration of major viral products are indicated 
on the left side, whereas the molecular marker sizes are reported on the right.
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grossly influence the VLP morphology significantly. Both
VLP populations appeared composed of immature and
mature viral particles, the latter bearing the typical elec-
tron dense conical cone structures. Of note, in both cell
cultures, the presence of immature VLPs raised signifi-
cantly with the cell passages (not shown)
In conclusion, our data indicate that, upon induction, 18-
4s cells produce HIV-1 VLPs whose morphology was not
influenced by the high levels of incorporated NefG3C-
GFP molecules.
Cytofluorimetric detection of fluorescent NefG3C-GFP 
VLPs
Next, we developed a rapid and sensitive assay for the
detection of the VLP-associated fluorescence based on the
ability of aldehyde latex beads to specifically bind lipid
enveloped micro- and nanoparticles. Similar tests were
previously applied to the analysis of exosomes [27], and
here we originally provide evidence that such a method
can be fruitfully exploited for the analysis of VLPs. In
detail, we incubated clarified supernatants from induced
18-4s cells with the aldehyde latex beads at r.t. that, 1–2
hours later, were extensively washed and analyzed by
FACs. The representative results reported in Figure 6A
demonstrate that this assay can detect as few as 25 ng of
18-4s VLPs measured as CAp24 contents. The possible
presence of free NefG3C-GFP molecules did not interfere
with the FACs measurements since no fluorescence
increase was found associated to the beads incubated with
the supernatants from induced 18-4s cells previously
cleared from VLPs by ultracentrifugation as compared
Transmission electron microscope analysis of VLPs released by 18-4s cells Figure 5
Transmission electron microscope analysis of VLPs released by 18-4s cells. Thin section transmission electron 
microscope analysis of 293/RGP (A) and 18-4s cells (B) two days after induction. Relevant morphologic details regarding the 
produced viral particles were enlarged in the respective inserts. Bars mark 2 µM and 0.5 µM in the low- and high magnification 
images. respectively.BMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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with the control supernatants (Figure 6B). In addition, the
actual binding of VLPs to the beads was confirmed by the
specific labeling of either virion-associated CAp24 or Nef
with monoclonal Abs we observed only upon a permeabi-
lization step (Figure 6C).
We exploited such VLP analytical method to compare the
fluorescence associated with NefG3C-GFP VLPs with that
of VLPs incorporating GFP-Vpr. To this aim, 293T cells
were co-transfected with a HIV-1 packaging vector
together with the vector expressing the respective GFP-
related product, and the released VLPs purified on a 20%
sucrose cushion. Then, equivalent amounts of VLPs, as
measured by a quantitative anti-CAp24 ELISA, were incu-
bated with aldehyde latex beads, and the fluorescence
evaluated by FACs. As shown in Figure 7A, beads binding
NefG3C-GFP VLPs showed more than 3-fold increased
fluorescence as compared with the GFP-Vpr VLPs. This
was not the result of different transfection efficiencies in
the respective producer cells, where the GFP-related prod-
ucts appeared equally expressed (not shown), but is con-
sistent with the VLP Western blot analysis depicted in
Figure 1B.
Next, to assess whether the NefG3C-GFP system could be
applied also to other retroviruses, we evaluated the levels
of incorporation of NefG3C-GFP molecules in Moloney
Leukemia Virus (MLV) particles, that were shown to effi-
ciently incorporate HIV-1 Nef [28]. To this aim, we com-
pared the fluorescence associated to VLPs produced in the
presence of wt Nef-GFP with that of NefG3C-GFP. 293T
cells were co-transfected with the vector expressing the
respective GFP-related product together with a Gag-Pol
MLV packaging construct, and equivalent amounts of
purified VLPs, as measured by the Mn++ dependent reverse
transcriptase assay, were incubated with aldehyde latex
beads. The FACs analysis (Figure 7B) clearly showed low
levels of fluorescence associated with wt Nef-GFP MLV
VLPs, while strong GFP-related signals arose from the
beads binding the NefG3C-GFP MLV VLPs. This result
represents the proof-of-principle that the NefG3C-GFP
approach could be of utility also for non HIV-1 retroviral
systems.
Pseudotyped 18-4s VLPs efficiently deliver NefG3C-GFP 
molecules in target cells
Finally, we were interested in establishing whether and
how efficiently 18-4s VLPs can fluorescently mark the tar-
get cells upon viral entry. To this aim, 18-4s VLPs pseudo-
typed with either the VSV-G (in its wt form or with a
mutant defective for the fusion activity) [29] or the HIV-1
X4 Env receptors were produced by transfecting 18-4s cells
with the appropriate expression vectors and, 6 to 8 hours
later, treating the cells with PonA and sodium butyrate. Of
note, the liposome-mediated transfection worked effi-
ciently in 18-4s as well as in 293/RGP parental cells, rang-
ing the expression of transfected receptors from 60 to
95%, as measured by FACs (not shown). Thus, 18-4s cells
remained a good recipient for the expression of ectopic
sequences. VLP preparations were preventively character-
ized in terms of their contents of both NefG3C-GFP mol-
ecules and the respective receptors (Figure 8A). Next, we
assessed that 250 ng/105 cells of VLPs pseudotyped with
the wt but not with the fusion-mutant VSV-G rendered the
majority of challenged cells fluorescent at the FACs analy-
sis as early as 2 hours after the VLP treatment. (Figure 8B).
In addition, the pre-treatment of target cells with either
bafilomycin A1 or chloroquine, i.e. two drugs inhibiting
the VSV-G mediated endocytic fusion by raising the endo-
somal/lysosomal pH, led to a clear reduction of the fluo-
rescence of the challenged cells (Figure 8B). We interpret
the residual cell-associated fluorescence as the product of
the accumulation of fluorescent VLPs in not functional
endosomes/lysosomes rather than of a suboptimal cell
response to the inhibitors. In fact, similar outcomes were
obtained also by raising the drug concentrations up to 5-
fold (not shown).
Conversely, and as expected, the viral entry driven by HIV-
1 Env appeared significantly less efficient, considering
that 1 µg/105 cells of HIV-1 Env pseudotyped VLPs ren-
dered fluorescent about 40% of target cells that also inter-
nalized lower amounts of NefG3C-GFP, as indicated by
the lower mean fluorescence intensity (Figure 8C). The
idea that the fluorescence detected in target cells indeed
relied on authentic viral fusion events was strengthen by
the inhibition we observed upon the pre-incubation of
HIV-1 Env VLPs with either the 17b anti-Env gp 120 (Fig-
ure 8C), or the 2F5 anti-Env gp41 neutralizing mAbs (not
shown).
The analysis at the fluorescence microscope of the target
cells (Figure 9A) showed a strong fluorescence associated
with (VSV-G) NefG3C-GFP VLP challenged cells, while
the fluorescence levels appeared significantly fainter in the
cells challenged with the X4 Env pseudotyped VLPs.
Finally, the confocal microscope analysis formally con-
firmed that the fluorescence associated with the target
cells originated from an authentic cell internalization of
fluorescent VLPs pseudotyped with VSV-G (Figure 9B), or
with HIV-1 Env receptors (not shown). Besides the above
described challenges carried out with VLPs lacking func-
tional receptors, such results were validated also by the
lack of fluorescence we observed in cells challenged with
either VSV-G or X4 Env pseudotyped VLPs and incubated
at 4°C (not shown). Finally, the results obtained in
CEMss cells were also reproduced in U937 cells, primary
CD4+ lymphocytes, or human primary monocyte-derived
macrophages (not shown).BMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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Cytofluorimetric analysis of VLPs released by 18-4s cells Figure 6
Cytofluorimetric analysis of VLPs released by 18-4s cells. (A) Hundred microliters of supernatants from induced 18-4s 
cells were clarified, adjusted to 400 ng of CAp24 contents, two-fold serially diluted in complete medium, incubated with alde-
hyde latex beads, and finally analyzed by FACs (slopes b). As control, supernatants from 293/RGP cells adjusted for equal VLP 
contents were used (slopes a). (B) The supernatants from induced 18-4s (slope b) and, as control, from 293/RGP cells (slope a) 
were cleared from a total of 400 ng of VLPs by ultracentrifugation, and then analyzed by FACs upon incubation with aldehyde 
latex beads. (C) Hundred ng of 18-4s VLPs were incubated with aldehyde latex beads and labeled with either KC57 PE-conju-
gated anti-CAp24 (on the left) or anti-Nef mAbs # 6.2 (on the right) and, in a second step, with PE-conjugated goat anti-mouse 
IgG. Histograms refer to the FACs analysis of aldehyde latex beads incubated with supernatants of 18-4s cells either non 
induced (a) or induced but in the absence (b) or presence (c) of the permeabilization step before the Ab labeling.
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Comparative analysis of the GFP-related fluorescence associated with NefG3C-GFP and GFP-Vpr VLPs Figure 7
Comparative analysis of the GFP-related fluorescence associated with NefG3C-GFP and GFP-Vpr VLPs. (A) 
The indicated amounts of NefG3C-GFP (b) and GFP-Vpr (c) VLPs purified from the supernatants of transfected 293T cells 
were incubated with aldehyde latex beads and then analyzed by FACs. As control, the analysis of beads incubated with equiva-
lent amounts of void VLPs (a) was included. The mean fluorescence values for each slope are indicated in the respective panels. 
The results are representative of data obtained from two independent experiments. (B) Analysis of the GFP-related fluores-
cence associated with MLV-based VLPs produced in cells expressing NefG3C-GFP (b) or wt Nef-GFP (c). 293T cells were co-
transfected with a MLV packaging construct and a vector expressing wt Nef-GFP or NefG3C-GFP. VLPs released in the super-
natants were purified, and the relative amounts quantified through the Mn++ dependent reverse transcriptase assay. Amounts 
of VLPs equivalent to 106 or 5 × 105 cpm were incubated with aldehyde latex beads and analyzed by FACs as compared to 
equal amounts of void MLV VLPs (a). The mean fluorescence values for each slope are indicated in the respective panels. The 
results are representative of data obtained from two independent experiments.
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Efficient delivery of the NefG3C-GFP-related fluorescence by pseudotyped 18-4s VLPs Figure 8
Efficient delivery of the NefG3C-GFP-related fluorescence by pseudotyped 18-4s VLPs. (A) Western blot analysis 
of NefG3C-GFP pseudotyped VLPs. Hundred ng of differently pseudotyped VLPs were analyzed by Western blot for the pres-
ence of NefG3C-GFP and of the respective receptors. The migration of major viral products is indicated on the left side, 
whereas the molecular marker sizes are reported on the right. (B) FACs analysis of CEMss cells 2 and 4 hours after the chal-
lenge with 250 ng/105 cells of NefG3C-GFP VLPs pseudotyped with VSV-G or, as control, with its mutant defective for the 
fusion activity (fm). As control, in a separate experiment the same amounts of (VSV-G) VLPs were used to challenge cells 
untreated (Ctrl) or pre-treated for 2 hour at 37°C with either 100 nM bafilomycin A1 or 50 µM chloroquine. Cells were ana-
lyzed 2 hours after the challenge. Bars were drawn at the highest fluorescence levels of untreated cells. Percentages of GFP 
positive cells are reported in the respective plots. (C) FACs analysis of CEMss cells 2 and 4 hours after the challenge with 1 µg/
105 cells of NefG3C-GFP VLPs pseudotyped with X4-tropic HIV-1 Env or, as control, without receptors ("Null"). As control, in 
a separate experiment the same amounts of HIV-1 Env VLPs were incubated for 1 hour at 4°C with the 17b anti-Env gp120 
neutralizing mAb, or with an isotype matched irrelevant mAb (Ctrl) before the cell challenge. Cells were analyzed 4 hours after 
the challenge. Bars were drawn at the highest fluorescence levels of untreated cells. Percentages of GFP positive cells are 
reported in the respective plots.
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Taken together, our data support the idea that the 18-4s
cells could be a useful reagent for the study of early events
correlating with the viral entry mediated also by heterolo-
gous virus receptors.
Discussion
To the best of our knowledge, this is the first report
describing the isolation of a stable cell population releas-
ing fluorescent HIV-1 based VLPs. The biological features
of 18-4s cells do not diverge significantly from those of
the 293/RGP parental cells [23], except for a more strin-
gent requirement of sodium butyrate for the VLP produc-
tion. Sodium butyrate is known acting on methylated
promoter sequences and/or on surrounding heterochro-
matinic DNA, ultimately leading to the re-activation of
silenced genes. This is thought occurring through the
hyperacetylation of histone and non-histone nuclear pro-
teins [30,31]. We observed that, in the one hand, the
parental 293/RPG cells significantly decreased the levels
of VLP release with passages. This was possibly due to a
progressive transcriptional silencing of HIV-1 regulatory
and/or structural genes, and was efficiently reverted by
Fluorescence and confocal microscope analysis of VLP challenged cells Figure 9
Fluorescence and confocal microscope analysis of VLP challenged cells. (A) Fluorescence microscope analysis of 
CEMss cells 4 hours after the challenge with VSV-G (on the left) or X4 HIV-1 Env (on the right) pseudotyped NefG3C-GFP 
VLPs after DAPI labeling. The bars mark 10 µM (B) Confocal microscope analysis of CEMss cells 4 hours after the challenge 
with (VSV-G) NefG3C-GFP VLPs. The same field was scanned at three section plans. The images are the result of the compu-
ter-assisted analysis carried out by overlapping the images obtained with visible and fluorescence lights. The bars mark 10 µM.
A
HIV-1 Env VSV-G
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sodium butyrate. This treatment, on the other hand, was
absolutely required for the release of VLPs from 18-4s
cells, likely due to the silencing of HIV-1 genes already
operative at the time of the cell isolation.
The FACs analysis revealed that 18-4s cells are composed
by two clearly distinguishable sub-populations in terms of
the expression of both NefG3C-GFP and ∆NGFr. In partic-
ular, on the basis of the mean fluorescent intensities we
measured by FACs, the bright sub-population seemed to
accumulate both products about 5-fold more efficiently
than the dull one. Concerning the most relevant expres-
sion of NefG3C-GFP, we noticed that with passages, the
bright sub-population tended to reduce, meanwhile
appearing a detectable fraction of GFP negative cells.
Again, this is likely the consequence of the silencing of the
NefG3C-GFP sequences rather than to their loss since also
in this case the treatment with sodium butyrate resulted in
the restoration of the original GFP profile (not shown).
We have no obvious explanations for the mechanisms
underlying the production of the two sharply distinct 18-
4s cell sub-populations, even if it may be conceivable that
this reflects the differences in the number and/or sites of
the integration of the plasmid vectors. In addition, the
consequent protein overproduction might be associated
with an impaired protein degradation efficiency, thus
resulting in steady-state protein levels overriding the real
differences in the numbers of integrated vectors.
The 2–3 fold decreased levels of VLP release from the 18-
4s cell line compared with the parental cells appeared
consistent with the reduced viral production we observed
in transient transfection experiment (not shown), and was
possibly due to some steric hindrance occurring during
the assembling/release process as the consequence of the
high levels of NefG3C-GFP incorporation. Of note, the
data from EM analysis showed that this did not lead to sig-
nificant morphologic alterations of VLPs that in both
cases appeared as both mature and immature particles. In
this regard, we cannot formally exclude that the signifi-
cant presence of immature viral particles depended at
least in part on a slow kinetic of maturation rendering
more difficult the detection of mature particles through
the electron microscope observation of ultra-thin cell sec-
tions we performed.
The analyses we carried out by FACs and by fluorescence
and confocal microscopes consistently indicated that the
cells targeted by pseudotyped 18-4s VLPs become fluores-
cent as early as 2 hours after the challenge. Generally
speaking, the great part of HIV-1 particles undergo cell
internalization through a receptor independent endocyto-
sis leading to lysosome degradation [10,32], whose inhi-
bition, in fact, increases HIV infection [33,34]. In the
analysis of the VLP entry we performed, it is worthy of
note that the 18-4s VLPs pseudotyped with the fusion
defective VSV-G or with "null" VLPs did not induce a sig-
nificant increase of the cell fluorescence compared with
the mock challenged cells. These results, together with
those obtained with chemical inhibitors or neutralizing
antibodies, strongly suggests that the cell fluorescence we
detected basically relied on the completion of the virus
fusion events with the release into the cytoplasm of the
fluorescent molecules, a conclusion also supported by our
results from the confocal microscope analysis.
We feel the relevance of the 18-4s cells stands in two main
fields of application. The first could be the study of the
mechanisms and dynamic of viral entry, and the second
regards the screening of antiviral compounds targeting the
late HIV replication events. In particular, the possibility to
pseudotype HIV-1 VLPs with a wide array of viral recep-
tors could allow gaining more insights on the not yet fully
elucidated mechanism of entry of viruses of different spe-
cies. This is for instance the case of Human hepatitis C
virus, whose cell receptor/co-receptors have still to be
unambiguously identified (for a review, see [35]). In this
regard, the cell fluorescence generated by the VLP entry
would be a more stringent marker of viral entry compared
with the in use systems relying on the lentivirus-mediated
transduction of gene markers whose expression can be
restricted by host cell factors. On the other hand, the
rather simple protocol for the detection of fluorescent
VLPs by FACs we developed renders 18-4s cells a both safe
and powerful tool for large-scale screenings of new anti-
HIV compounds electively targeted to the assembly/
release processes. Thus, 18-4s cells are anticipated to be a
useful reagent for multiple purposes that will be freely
available upon request.
Furthermore, from the point of view of the basic virology,
the possibility to analyze viral particles by FACs as here
described opens the way towards new rapid and accurate
approaches in the investigation on the molecular compo-
sition of enveloped viruses in terms of both viral and
virus-associated cell products.
Finally, on the basis of the results we obtained with the
MLV-based VLPs, we expect that the NefG3C-GFP
approach could be applied also to different retroviral sys-
tems close to HIV-1(e.g., HIV-2, SIV) and MLV.
Conclusion
Fluorescent VLPs produced by the 18-4s cell line can be
considered a novel reagent useful for studies of virus entry
also in fields other than HIV. In addition, by exploiting a
FACs-based assay for the detection of the VLP fluorescence
we here originally describe, 18-4s cells would be of a great
utility for screening new generations of antiviral com-
pounds targeting late events of HIV-1 replication.BMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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Methods
Molecular constructs, cell lines and cultures
The vector expressing the NefG3C-GFP mutant was gener-
ated from the pcNefsg25GFP vector using the quick-
change kit (Stratagene, La Jolla, CA), and the mutation
was checked by sequencing. 18-4s cells were recovered by
the liposome (Lipofectamine-2000, Invitrogen, Carlsbad,
CA)-mediated transfection of the HIV-1 packaging 293/
Rev-Gag-Pol cells [23] with vectors expressing NefG3C-
GFP and the human Nerve Growth factor receptor trun-
cated in its intracytoplasmic domain [36]. 293T, 293/Rev-
Gag-Pol, and 18-4s cells were grown in Dulbecco's modi-
fied Eagle's medium supplemented with 10% decomple-
mented Fetal Calf Serum (dFCS). CEMss and U937 cells
were cultivated in RPMI supplemented with 10% dFCS.
Human primary lymphocytes were isolated from periph-
eral blood mononucleated cells (PBMC) isolated from
20–40 year-old healthy male blood donors. Lymphocytes
were selected from PBMC using an immunomagnetic-
based selection kit from Miltenyi Bioytec (Auburn, CA).
PBLs were activated with 2 µg/ml phytohemagglutinin
(Sigma-Aldrich, Milan, Italy), and cultivated in RPMI con-
taining 20% of dFCS in the presence of 100 U/ml of
recombinant human IL-2 (Roche, Nutley, NJ). Monocytes
were isolated by 1 h adherence of PBMC, followed by
immunomagnetic depletion of non-monocytic cells car-
ried out through a Miltenyi selection kit. Monocytes were
cultivated in 48-well plates in RPMI supplemented with
20% dFCS.
VLP and HIV-1 production, purification, titration, and 
challenge
Preparations of VLPs were obtained from either 293T,
293/RGP, or 18-4s cells. In the first instance, 293T cells
were co-transfected by liposomes (Lipofectamine-2000,
Invitrogen) with the pCMV∆R8.74 HIV-1 packaging vec-
tor [37] and the immediate-early CMV promoted vectors
expressing either NefG3C-GFP, wt Nef-GFP [21], GFP-Vpr
[9], or the NL4-3 wt Nef. From 48 to 72 hours later, the
supernatants were harvested, clarified, and concentrated
by ultracentrifugation on 20% sucrose cushion 100,000 g,
2 h at 4°C. Alternatively, VLP preparations were obtained
from the supernatants of either 293/RGP or 18-4s cells
two or three days after the induction with 5 mM sodium
butyrate (Sigma-Aldrich, St. Louis, MO) and/or 2 µM of
Ponasterone A (PonA) (Sigma-Aldrich). Pseudotyped
VLPs from 18-4s cells were obtained by transfecting 5 to
10 µg of the vectors expressing the respective viral receptor
(i.e., VSV-G or X4 Env HIV-1 from the HXB-2 isolate, both
obtained from the NIH AIDS Research and Reference Rea-
gent Program) and, 4 to 6 hours later, by inducing the
cells with sodium butyrate and PonA. Twenty-four hours
later, the supernatants were replaced with fresh medium
containing the inducers, and VLP containing supernatants
were harvested 48 and 72 hours after the induction, clari-
fied, and purified as here above described. The purifica-
tion of 18-4s VLPs was performed by a iodixanol gradient.
Briefly, VLPs purified by a 20% sucrose cushion were
loaded on a 6 to 35 % discontinuous gradient of Optiprep
(Axis-Shield, Oslo, Norway). Samples were ultracentri-
fuged at 37,000 rpm at 4°C for 90 min on a SW41 rotor,
and 700 µl fractions were collected from the top. These
where then 1:5 diluted with PBS, pelletted, re-suspended
in 100 µl, and finally 30 µl analyzed by both anti-Nef and
anti-Gag Western blot.
VLP preparations were titrated by measuring the HIV-1
CAp24 contents by quantitative ELISA (Abbott, Abbott
Park, Illinois), and by the reverse transcriptase assay [38].
For the cell challenges, VLPs were adsorbed by spinocula-
tion at 150 g for 30 min at room temperature (r.t.). After-
wards, the cell cultures were re-fed by adding fresh
medium, and incubated at 37°C. Finally, the cells were
treated for 15 min with trypsin at 37°C, fixed, and ana-
lyzed by FACs. Inhibition experiments were carried out by
pre-treating cells at 37°C for 2 h with either bafilomycin
A1 (Sigma-Aldrich), or chloroquine (Sigma-Aldrich) for
the VSV-G VLPs, or by pre-incubating HIV-1 Env VLPs for
1 hour at 4°C with the 17b or 2F5 neutralizing mAbs (200
ng for 1 µg of VLPs), both obtained from the NIH AIDS
Research and Reference Reagent Program
HIV-1 NL4-3 virus preparations were recovered by tran-
siently transfecting 293T cells with the pUc/NL4-3 infec-
tious molecular clone [39]. HIV-1 particles recovered
from the supernatants were purified and titrated as here
above described.
Western blot analysis
Both cells and purified VLP preparations were lysed in
PBS, 1% Triton-X100 in the presence of anti-proteolytic
agents. For the preparation of cytoplasmic extracts, whole
cell lysates were centrifuged at 6,000 g for 10 min at 4°C,
and the supernatants frozen at -80°C. Aliquots of 30 µg of
total cell proteins were separated in 10% SDS-PAGE,
thereby undergoing the immunoblot analysis (Western
blot). rNef preparations were obtained and quantified as
previously described [40]. The following mono- or poly-
clonal Abs served for the revelation of both VLP- and cell-
associated HIV-1 products: pooled strongly reactive antis-
era from HIV-1 positive AIDS patients; ARP 444 sheep
anti-Nef antiserum from Mark Harris, University of Leeds,
Leeds, UK; polyclonal anti-VSV-G protein from Immunol-
ogy Consultant Laboratories (Newberg, OR); anti-HIV-1
Env gp120 4G10 mAb from the NIH AIDS Research and
Reference Reagent Program; and anti-GFP mAb from
Clontech (Clontech Laboratories, Palo Alto, CA). In some
experiments, VLPs were treated with subtilisin A to digest
contaminating cell debris and proteins possibly non spe-
cifically adsorbed to the VLP envelope. Briefly, purifiedBMC Biotechnology 2006, 6:52 http://www.biomedcentral.com/1472-6750/6/52
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virus suspensions were supplemented with an equal vol-
ume of 2 mg of subtilisin A (Sigma-Aldrich)/ml in 40 mM
Tris-HCl (pH 8.0), 2 mM CaCl2, and incubated 2 hours at
37°C. The digestion was stopped by addition of phenyl-
methylsulfonyl fluoride to 5 µg/ml.
Fluorescence, confocal, and electron microscope analyses
For the analysis at the fluorescence microscope, 18-4s cells
were placed on poly-L-Lysine (Sigma-Aldrich) coated
cover glass. Cells were then fixed in 4% paraformaldehyde
(Sigma-Aldrich) in PBS and quenched for 10 min with 0.1
M glycine in PBS. Cover slips were then mounted to slides
using anti-fade mounting medium, after, in the cases of
the 4'-6-Diamidino-2-phenylindole (DAPI, Vector Labo-
ratories, Burlingame, CA.) labeling, cell permeabilization
with 0.1% Triton-X100 (Sigma-Aldrich) in PBS. Finally,
the cells were observed using a Zeiss Axioskop 2 plus flu-
orescence microscope. For the confocal microscope anal-
ysis, cells were fixed with 2% v/v of formaldehyde in PBS,
and both phase contrast and fluorescence images were
taken by an Olympus IX-81 device. For transmission elec-
tron microscopy (TEM) examination, cells were fixed in
2.5% cacodylate-buffered (0.2 M, pH 7.2) glutaraldehyde
for 20 min at r.t. and post-fixed in 1% OsO4 in cacodylate
buffer for 1 h at r.t. Specimens were then dehydrated
through graded series of ethanol solutions and embedded
in Agar 100 resin (Agar Aids, Cambridge, U.K.). After
staining with uranyl acetate and lead citrate, ultra-thin
sections were observed with a Philips 208 electron micro-
scope at 80 kV.
FACs analysis of cells and VLPs
For the detection of the human Nerve Growth factor
receptor, 3 × 105cells were incubated with a 1:100 dilu-
tion of the 20.4 mAb (ATCC, Rockville, MD, USA) or, as
control, with a isotype-matched, specie-specific irrelevant
mAb for 1 h at 4°C. Thereafter, cells were washed and
labeled for 1 h at r.t. with a l:100 dilution of phycoeryth-
rin (PE)-conjugated goat anti-mouse IgG. Cell popula-
tions were finally fixed with 2% formaldehyde in PBS and
analyzed by FACs. For the detection of HIV-1 Gag-related
products, the cells were treated with Permeafix (Ortho
Diagnostic, Raritan, NJ) for 30 min at r.t., and then
labeled for 1 h at r.t. with a l:100 dilution of PE-conju-
gated anti-CAp24 KC-57 mAb (Coulter Corp. Hialeah,
FL). For the VLP detection by FACs, 5 µl of surfactant-free
white aldehyde/sulfate latex beads (Invitrogen Molecular
Probes, Eugene, ON) were added to 100 µl of clarified
supernatants. The mixture was incubated at r.t. for 1–2 h
on a rotating plate, and therefore the samples were
washed once with PBS buffer. For the direct FACs analysis,
the washed beads were finally resuspended in PBS-2% for-
maldehyde. Alternatively, the VLP-coupled beads were
treated with Permeafix for 30 min at r.t., and then incu-
bated either with a l:100 dilution of PE-conjugated of the
anti-CAp24 KC-57 mAb, or with a 1:30 dilution of the
anti-Nef mAb # 6.2 from the NIH AIDS Research and Ref-
erence Reagent Program.
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